Open AccessDEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis
Author(s) -
Qu Di,
Cui Feng,
Lu Dan,
Yang Yu,
Xu Yuqing
Publication year - 2019
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13867
Subject(s) - hepatocellular carcinoma , metastasis , cancer research , wnt signaling pathway , carcinogenesis , downregulation and upregulation , cancer , in vivo , cell growth , biology , medicine , signal transduction , gene , microbiology and biotechnology , genetics
DEP domain containing 1 ( DEPDC 1) protein is a novel oncoantigen upregulated in multiple types of cancers which present oncogenic activity and high immunogenicity. However, the function and therapeutic potential of DEPDC 1 in hepatocellular carcinoma ( HCC ) remain unclear. In the present study, we showed that DEPDC 1 was frequently upregulated in HCC and associated with cancer diagnosis and poor prognosis for HCC patients. Moreover, DEPDC 1 promotes HCC cell proliferation in vitro as well as carcinogenesis in vivo. Notably, DEPDC 1 overexpression also increases the neoplasm metastasis ability of HCC cells both in vivo and in vitro. Gene set enrichment analysis results showed that DEPDC 1 expression is positively correlated with K‐ RAS signal pathway, pathways in cancer and WNT /β‐catenin signal pathway, all of which are closely associated with specific cancer‐related gene sets. Our study provides the basis for further investigation of the molecular mechanism by which DEPDC 1 promotes the development and metastasis of HCC .